Narrative review / 2000
A review examined the antiangiogenic shark cartilage extract AE-941, which is under phase III evaluation for renal cell carcinoma and non-small cell lung cancer.
This commentary reviews current knowledge regarding the anticancer properties of cartilage. It presents the characteristics of AE-941, a standardized water-soluble extract derived from shark cartilage that constitutes less than 5% of crude cartilage. AE-941 is described as a multifunctional antiangiogenic product containing biologically active molecules. At the time of publication, it was under phase III clinical trials for refractory renal cell carcinoma in Europe and North America, and for metastatic non-small cell lung cancer in North America.
- Study type
- Narrative review / commentary
- Who was studied
- Patients with cancer (including refractory renal cell carcinoma and lung cancer)
- What was measured
- Anticancer and antiangiogenic properties of shark cartilage extract AE-941
THE PAPER
Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills?
Gingras D, Renaud A, Mousseau N, Béliveau R. Cancer Metastasis Rev, 2000.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.